Market Place
Sourcing Support
Idera Announces Name Change to Aceragen & Provides Near-Term Strategic Outlook
17 Jan 2023 //
GLOBENEWSWIRE
Aeterna discontinues vaccine development; Idera rebrands as Aceragen
17 Jan 2023 //
ENDPTS
Idera Pharma Reports 3Q 2022 Financial Results and Provides Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
Idera buys rare-disease-focused Aceragen in all-stock deal
30 Sep 2022 //
FIERCEBIOTECH
Idera Pharmaceuticals Acquires Aceragen
28 Sep 2022 //
GLOBENEWSWIRE
Idera Stops Enrollment in Phase 2 Melanoma Trial Following Positive Early Data
19 May 2022 //
TRIALSITENEWS
Idera Shares Positive Results from Investigator-Sponsored Trial in Melanoma
17 May 2022 //
GLOBENEWSWIRE
Idera Pharma Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Idera Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Idera`s only asset flounders as biotech, AbbVie end enrollment
16 Dec 2021 //
FIERCEBIOTECH
Idera Pharmaceuticals Announces Corporate Updates
18 May 2021 //
GLOBENEWSWIRE
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial
19 Mar 2021 //
GLOBENEWSWIRE
Idera says tilsotolimod combo flops in anti-PD-1 refractory melanoma study
18 Mar 2021 //
GLOBENEWSWIRE
Idera Announces $5.0 M in Further Proceeds from Private of up to $20.7 M
15 Dec 2020 //
GLOBENEWSWIRE
Titan Pharmaceuticals, Idera Pharmaceuticals leads healthcare gainers
20 Nov 2020 //
SEEKING ALPHA
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
15 Sep 2020 //
GLOBENEWSWIRE
Idera Reports Second Quarter Financial Results and Provides Corporate
04 Aug 2020 //
GLOBENEWSWIRE
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
15 Jul 2020 //
GLOBENEWLSWIRE
Idera Announces Preliminary Data From and Planned Continuation ILLUMINATE-206
02 Jun 2020 //
GLOBENEWSWIRE
Idera`s tilsotolimod shows positive effect in mid-stage melanoma study
21 Apr 2020 //
SEEKINGALPHA
Idera Pharmaceuticals completes enrollment in registrational trial
05 Mar 2020 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.